Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

FRAX597

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Afraxis, Roche, Scripps Research Institute

Drug class:

P21-activated kinase inhibitor

Related drugs:

‹

›

PAK1 overexpression	T Cell Non-Hodgkin Lymphoma	PAK1 overexpression	T Cell Non-Hodgkin Lymphoma	FRAX597 + PF-3758309 Resistant: C3 – Early Trials FRAX597 + PF-3758309 Resistant : C3	FRAX597 + PF-3758309 Resistant: C3 – Early Trials FRAX597 + PF-3758309 Resistant : C3
PAK2 overexpression	T Acute Lymphoblastic Leukemia	PAK2 overexpression	T Acute Lymphoblastic Leukemia	FRAX597 + PF-3758309 Sensitive: D – Preclinical FRAX597 + PF-3758309 Sensitive : D	FRAX597 + PF-3758309 Sensitive: D – Preclinical FRAX597 + PF-3758309 Sensitive : D
HRAS G13R	Thyroid Gland Carcinoma	HRAS G13R	Thyroid Gland Carcinoma	FRAX597 Sensitive: D – Preclinical FRAX597 Sensitive : D	FRAX597 Sensitive: D – Preclinical FRAX597 Sensitive : D